Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 105,978

Document Document Title
WO/2015/086866A1
The invention relates to the use of compounds of the 12-deoxyphorbol family or a pharmacologically active salt of said compounds, for stimulating the proliferation of neural precursors or neural stem cells in a culture. The invention als...  
WO/2015/087927A1
A patch which is provided with a patch member and a cover member, wherein: the patch member is provided with a support layer and a drug reservoir layer which is laminated on one surface of the support layer and which contains both a drug...  
WO/2015/086719A1
The present invention relates generally to supporting the optimal development of children through nutrition and cognitive exercise. In particular, the present invention relates to a growing-up milk composition comprising per daily dose a...  
WO/2015/085909A1
Provided in the present invention is a aminopyrimidine heterocyclic compound with adenosine receptor antagonist activity, comprising the compound and pharmaceutically acceptable salts, various isotopes, isomers and crystal structures the...  
WO/2015/083750A1
Provided is a composition for activating neuropoiesis or neuron proliferation. In one or more embodiments, the composition contains, as the active ingredient, a compound having a DYRK inhibiting ability, a prodrug thereof, or a pharmaceu...  
WO/2015/083816A1
 Provided is a new NK3 receptor selective ligand which is expected to have high activity and high selectivity, and to act in a sustained manner in vivo. A compound expressed by formula (I) X1 - A2 - A3 - X4 - X5 - Met - NH2 [the symb...  
WO/2015/083736A1
 Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method f...  
WO/2015/083094A1
The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparati...  
WO/2015/082533A1
The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alky...  
WO/2015/085077A1
Methods of achieving sustained memory improvements and sustained improvement in learning abilities in an infant are provided. The methods comprise administering an effective amount of sialic acid to an infant or a preterm infant until at...  
WO/2015/083129A1
There are described derivatives of gamma-hydroxybutyric acid (GHB), their preparation and their use as GHB pro drugs in the treatment of ethanol addiction. In particular, the derivatives of gamma-hydroxybutyric acid (GHB) have formula (I).  
WO/2015/082357A1
The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the ...  
WO/2015/085192A1
A preparation for treatment and/or prevention of seizures comprising a non-mammalian derived mixture of serine glycerophospholipids (PS) conjugates, wherein the mixture comprises (a) Eicosapentaenoic acid (EPA) conjugated to PS and (b) D...  
WO/2015/082370A1
The present invention provides processes to manufacture substituted l-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b- tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the inven...  
WO/2015/083070A1
The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2- yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2 -yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compo...  
WO/2015/083179A1
A process suitable for adoption to large scale manufacture of 1-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the sy...  
WO/2015/084908A1
The present invention relates to the field of stem cells. More specifically, the present invention provides methods and compositions useful for the highly efficient conversion of human stem cells to lineage-specific neurons. In a specifi...  
WO/2015/083071A1
The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1 H-benzo[d]imidazol- 2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol -2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, phar...  
WO/2015/082932A1
The present invention relates to opioid compounds, especially to C14 esters and ethers of naltrexone and analogues thereof. The present invention also relates to compositions, methods and medical uses that employ such compounds. More spe...  
WO/2015/081822A1
Disclosed are a 3-furyl-2-cyano-2-acrylamide derivative with epidermal growth factor receptor (EGFR) inhibitory activity and pharmaceutical acceptable salt thereof, together with preparation method therefor, pharmaceutical composition co...  
WO/2015/081850A1
Disclosed is an intravitreal injection drug delivery system for mouse nerve growth factor (mNGF), the system being characterized by comprising the mNGF and an ultrasonic contrast agent. Also disclosed is an application of the intravitrea...  
WO/2015/084161A1
Composition comprising a uridine source, an omega-3 PUFA for improving coordination, balance, grip strength or fine motor skills. The invention is directed to a combination of a uridine source and an omega-3-polyunsaturated fatty acid ha...  
WO/2015/083871A1
The present invention relates to a composition containing osmotin as an active ingredient for improving cognitive function. More specifically, in an Aβ-induced neurodegenerative mouse model administered with osmotin, Aβ-induced memory ...  
WO/2015/077905A1
Disclosed are compounds of Formula (A-a), or a salt thereof, Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also desc...  
WO/2015/078935A1
The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for parti...  
WO/2015/079459A1
Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmac...  
WO/2015/079390A1
The invention relates to 3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone (T I F) and achillolid A in prevention or treatment of Alzheimer's disease as well as other neurodegenerative diseases such as Parkinson's disease, Amyotrophic Lateral S...  
WO/2015/079224A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions conta...  
WO/2015/078374A1
The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as desc...  
WO/2015/078836A1
The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before.  
WO/2015/079241A1
The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use as an anticonvulsant and/or seizure suppressant, in particular in the treatment or prevention of (e.g. juvenile)epilepsy.  
WO/2015/079692A1
[Problem] To provide a compound having a formyl peptide receptor-like 1 (FPRL1) agonist effect. [Solution] The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The...  
WO/2015/077246A1
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurologica...  
WO/2015/075942A1
 The present invention provides a vesicle for delivering a drug to the brain, a conjugate, a composition containing same, and a method for administering same. A composition for administration to a subject according to a dosing regimen,...  
WO/2015/077611A1
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ΕΚβ). The disclosed compounds may be formulated as pharmaceutical compositions and administe...  
WO/2015/074494A1
Uses of ginsenoside-Rg3 in preparing medicine or health care products for preventing and treating brain dementia. The medicine or health care products comprise external preparation, oral preparation and injection containing ginsenoside-Rg3.  
WO/2015/076589A1
The present invention relates to a nerve-cell-regenerating pharmaceutical composition containing Vax protein as an active ingredient, and, more specifically, the Vax protein can advantageously be used as a nerve-cell-regenerating pharmac...  
WO/2015/074137A1
The disclosure provides methods of treatment of ocular inflammation or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent (such as a non-psych...  
WO/2015/074114A1
A method for minimising or preventing the induction of stress-related or stress- induced inappetance or inanition in an animal selected for a marketing or management practice.  
WO/2015/075515A1
The object of the present invention is a drug for the therapeutic treatment of tumours, also usable as diagnostic agent and therapeutic agent for the Alzheimer's disease. Such drug comprises a copper-64 radioisotope in its salt form, sai...  
WO/2015/077780A1
Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.  
WO/2015/075288A1
The invention pertains to the field of the study of apoptosis, especially the field of the prognosis and monitoring of diseases wherein apoptosis occurs. Concretely, the invention relates to a method for isolating apoptotic bodies from a...  
WO/2015/075155A1
The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of obsessions and/or compulsions in an individual.  
WO/2015/075003A1
The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a preparation for the reduction of both intra-operative and post-operative pain caused by castration of male pigl...  
WO/2015/076286A1
Provided is an ephedra extract stripped of ephedrine alkaloids, i.e., an ephedra extract from which ephedrine alkaloids have been removed, and a method for producing an ephedra extract stripped of ephedrine alkaloids. Also provided are a...  
WO/2015/075025A1
The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, ...  
WO/2015/076325A1
[Problem] To provide a novel glycyrrhetinic acid derivative. [Solution] A glycyrrhetinic acid derivative represented by formula (1). (1)  
WO/2015/077640A1
Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are di...  
WO/2015/076340A1
An injectable composition which comprises (1) a methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1 ,4]benzodiazepine-4-yl]propanoate or a salt thereof as an active ingredient and (2) one type or more of an additive selec...  
WO/2015/075082A1
The present invention deals with compounds of formula (I) which are novel uncharged reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use for reactivating human acetylcholinester...  

Matches 101 - 150 out of 105,978